SCHEMBL27218684

SCHEMBL27218684

COc1ccc(-c2nnc(CSc3nc(C)cc(N)n3)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 5/20 0.51
▸ MAPT P10636 4/20 0.51
▸ ESR1 P03372 1/20 0.51
▸ HPGD P15428 4/20 0.49
▸ ALDH1A1 P00352 6/20 0.48
▸ LMNA P02545 3/20 0.48
▸ HSD17B10 Q99714 5/20 0.48
▸ TSHR P16473 5/20 0.48
▸ HTT P42858 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ NPC1 O15118 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ TP53 P04637 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218873 0.90 SMN1; SMN2 (0.55) NPSR1MAPTESR1HPGDALDH1A1
SCHEMBL27218744 0.88 KDM4E (0.53) NPSR1MAPTESR1HPGDALDH1A1
SCHEMBL27218853 0.87 SMN1; SMN2 (0.60) NPSR1MAPTHPGDALDH1A1LMNA
SCHEMBL27218663 0.87 LMNA (0.62) NPSR1MAPTHPGDALDH1A1LMNA
SCHEMBL31494405 0.87 HSD17B10 (0.58) MAPTHPGDALDH1A1LMNAHSD17B10
SCHEMBL27218834 0.84 MAPT (0.56) NPSR1MAPTESR1HPGDALDH1A1
SCHEMBL27218698 0.83 MAPT (0.51) NPSR1MAPTESR1HPGDALDH1A1
SCHEMBL31494329 0.82 HTT (0.52) NPSR1MAPTHPGDALDH1A1LMNA
SCHEMBL27218829 0.82 HTT (0.52) NPSR1MAPTHPGDALDH1A1LMNA
SCHEMBL27218721 0.81 RAB9A (0.44) NPSR1MAPTHPGDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 NPSR1 200/4885MAPT 4802/4885ESR1 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback